{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:52:47Z","timestamp":1753883567502,"version":"3.41.2"},"reference-count":12,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Elevated 1,25-dihydroxyvitamin D (1,25(OH)2D) is a rare cause of non\u2013parathyroid hormone (PTH)\u2013mediated hypercalcemia seen in granulomatous disease, malignancy (most often lymphoma), or genetic mutations. Therapeutic options are limited. We report the case of a 67-year-old White man with nonmalignant, nongranulomatous, 1,25(OH)2D-mediated hypercalcemia treated successfully with cinacalcet. At presentation, he had hypercalcemia, hypercalciuria with recurrent nephrolithiasis, low PTH, elevated 1,25(OH)2D, and normal 25-hydroxyvitamin D. The 1,25(OH)2D levels were inappropriate in the setting of hypercalcemia with low PTH. Evaluations for sarcoidosis, tuberculosis, and malignancy were negative. Genetic testing showed biallelic variants in the CYP24A1 gene. Cinacalcet was trialed and showed normalization of calcium levels. On cinacalcet, biochemical indices showed a slight increase in 1,25(OH)2D and 24-hour urine calcium and mild decrease in PTH. He briefly experienced symptomatic hypocalcemia that resolved after reducing cinacalcet dose. Due to limited symptomatic benefit, he opted to stop cinacalcet. Additional follow-up showed intermittently elevated serum calcium levels after stopping cinacalcet, most recently 10.3\u2005mg\/dL. Cinacalcet may be a therapeutic option in nonmalignant, 1,25(OH)2D-mediated hypercalcemia. Further study is necessary to confirm efficacy, understand risks and benefits, and elucidate mechanism(s) of action.<\/jats:p>","DOI":"10.1210\/jcemcr\/luae022","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T08:45:52Z","timestamp":1710233152000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Oral Cinacalcet in Non-PTH Nonmalignant Hypercalcemia from Excess 1,25-Dihydroxyvitamin D"],"prefix":"10.1210","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4840-1802","authenticated-orcid":false,"given":"Sneha","family":"Mohan","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition and Department of Medicine, Mayo College of Medicine, Mayo Clinic , Rochester, MN 55905 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sheehan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Marshfield Clinic Health System, Weston Center , Weston, WI 54476 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Tebben","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition and Department of Medicine, Mayo College of Medicine, Mayo Clinic , Rochester, MN 55905 , USA"},{"name":"Division of Pediatric Endocrinology and Department of Pediatric and Adolescent Medicine, Mayo College of Medicine, Mayo Clinic , Rochester, MN 55905 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-7881","authenticated-orcid":false,"given":"Robert","family":"Wermers","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition and Department of Medicine, Mayo College of Medicine, Mayo Clinic , Rochester, MN 55905 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"issue":"5","key":"2024032207465726900_luae022-B1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1210\/er.2016-1070","article-title":"Vitamin D-mediated hypercalcemia: mechanisms, diagnosis, and treatment","volume":"37","author":"Tebben","year":"2016","journal-title":"Endocr Rev"},{"issue":"10","key":"2024032207465726900_luae022-B2","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1007\/s00198-016-3615-6","article-title":"Clinical and biochemical phenotypes of adults with monoallelic and biallelic CYP24A1 mutations: evidence of gene dose effect","volume":"27","author":"O\u2019Keeffe","year":"2016","journal-title":"Osteoporos Int"},{"issue":"1","key":"2024032207465726900_luae022-B3","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-20-0487","article-title":"Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift","volume":"10","author":"O\u2019Callaghan","year":"2021","journal-title":"Endocr Connect"},{"key":"2024032207465726900_luae022-B4","doi-asserted-by":"crossref","first-page":"110149","DOI":"10.1016\/j.mehy.2020.110149","article-title":"Oral cinacalcet responsiveness in non-parathyroid hormone mediated hypercalcemia of malignancy","volume":"143","author":"Sheehan","year":"2020","journal-title":"Med Hypotheses"},{"issue":"3","key":"2024032207465726900_luae022-B5","doi-asserted-by":"crossref","first-page":"E423","DOI":"10.1210\/jc.2011-1935","article-title":"Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy","volume":"97","author":"Tebben","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024032207465726900_luae022-B6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/EJE-21-0713","article-title":"Hypercalcemia due to CYP24A1 mutations: a systematic descriptive review","volume":"186","author":"Cappellani","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2024032207465726900_luae022-B7","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/j.ajkd.2018.12.026","article-title":"Fluconazole as a new therapeutic tool to manage patients with NPTIIc (SLC34A3) mutation: a case report","volume":"73","author":"Bertholet-Thomas","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2024032207465726900_luae022-B8","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1210\/jc.2016-4048","article-title":"CYP3A4 induction by rifampin: an alternative pathway for vitamin D inactivation in patients with CYP24A1 mutations","volume":"102","author":"Hawkes","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024032207465726900_luae022-B9","doi-asserted-by":"crossref","first-page":"E915","DOI":"10.1152\/ajpendo.00315.2009","article-title":"The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion","volume":"297","author":"Kantham","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"2024032207465726900_luae022-B10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrendo.2015.30","article-title":"The calcium-sensing receptor in bone\u2013mechanistic and therapeutic insights","volume":"11","author":"Goltzman","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2024032207465726900_luae022-B11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11154-021-09694-6","article-title":"The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies","volume":"23","author":"Chandran","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"issue":"Suppl 1","key":"2024032207465726900_luae022-B12","doi-asserted-by":"crossref","first-page":"A169","DOI":"10.1210\/jendso\/bvab048.341","article-title":"A challenging case of vitamin D toxicity responding to cinacalcet","volume":"5","author":"Addasi","year":"2021","journal-title":"J Endocr Soc"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/3\/luae022\/57020826\/luae022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/3\/luae022\/57020826\/luae022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T10:22:28Z","timestamp":1711102948000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luae022\/7626058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2,23]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luae022","relation":{},"ISSN":["2755-1520"],"issn-type":[{"type":"electronic","value":"2755-1520"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2024,2,23]]},"article-number":"luae022"}}